SLO County leads in solar, wind energy
Central Coast, Energy, Latest news, Top Stories, Top StoryThis article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Sientra faces disclosure lawsuits
Health Care & Life Science, Latest news, Law & Goverment, left, Top Stories, Tri-County Public CompaniesThis article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen reacquires rights to sell 3 drugs worldwide
Health Care & Life Science, Latest news, Tri-County Public CompaniesAmgen reacquired all rights to sell three drugs worldwide on Dec. 14. The Thousand Oaks-based biotech giant said it reacquired the rights to Prolia, Vectibix and Xgeva in 48 ccountries from British pharmaceutical company GlaxoSmithKline. The agreement includes large countries like Australia, China and Brazil. Prolia is designed to raise bone density in people with Read More →
Tri-county courses turn to footgolf
Latest news, Top Stories, West Ventura CountyThis article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen seeks European OK of biosimilar drug, partners with Merck on studies
East Ventura County, Health Care & Life Science, Latest news, Tri-County Public CompaniesAmgen announced two developments Dec. 4 that should help the Thousand Oaks-based biotech giant compete. Amgen said it is seeking approval from the European Medicines Agency for ABP 501, a biosimilar drug similar to Humira. Amgen also announced a partnership with New Jersey-based pharmaceutical Merck to partner in a non-Hodgkins lymphoma study using drugs from Read More →
Amgen bipolar about biosimilars
Health Care & Life Science, Latest news, Top Stories, Tri-County Public CompaniesThis article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
